natgillin/translations-raw huggingface dataset:
OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and/or possible fluid accumulation in your stomach or chest.
OHSS lahko postane resen z izrazito povečanimi jajčniki, zmanjšanim nastajanjem urina, pridobivanjem telesne mase, težavami dihanja in/ali morebitnim nabiranjem tekočine v trebuhu ali prsnem košu.
OHSS may become severe with clearly enlarged ovaries, decreased urine production, weight gain, difficulty in breathing and/or possible fluid accumulation in your stomach or chest.
OHSS lahko postane resen z izrazito povečanimi jajčniki, zmanjšanim nastajanjem urina, s pridobivanjem telesne mase, težavami dihanja in/ali morebitnim nabiranjem tekočine v trebuhu ali prsnem košu.
OHSS occurs when the ovaries over-respond to treatment, causing abdominal swelling and pain, nausea and diarrhoea.
Sindrom OHSS se pojavi, ko se jajčniki čezmerno odzovejo na zdravljenje, kar povzroči otekanje trebuha, bolečine v trebuhu, slabost in drisko.
OIC symptom improvement
Izboljšanje simptomov zaprtosti zaradi opioidov
OIC was confirmed through a two week run in period and defined as < 3 spontaneous bowel movements (SBMs) per week on average with constipation symptoms associated with at least 25% of bowel movements.
OIC je bila potrjena med dvotedenskim obdobjem uvajanja in je bila opredeljena kot povprečno < 3 spontana iztrebljanja na teden hkrati s simptomi zaprtosti pri vsaj 25 % iztrebljanj.
Oil adjuvanted vaccine
Cepivo z oljnim adjuvansom
Oily vehicle (vegetable oil).
Oljni vehikel (rastlinski izvor).
Oily vehicle (vegetable origin).
Oljni vehikel (rastlinski izvor)
Oily vehicle (vegetable origin): Triglycerides, medium chain Cottonseed oil.
Oljni vehikel (rastlinski izvor): Trigliceridi, srednje verige Olje bombaževega semena.
Ointment
Mazilo
Ointment.
Mazilo.
OL-LI 16 week
Odprta uvajalna faza 16 tednov
OL-LI 16 weeks
Odprta uvajalna faza 16 tednov
Olanzapine 15 mg in Study D1050231, quetiapine extended-release (XR) 600 mg in Study D1050233.
olanzapin v odmerku 15 mg v študiji D1050231, kvetiapin s podaljšanim sproščanjem (XR) v odmerku 600 mg v študiji D1050233
Olanzapine 2.5 mg
OLANZAPIN 2,5 mg
Olanzapine 7.5 mg
OLANZAPIN 7,5 mg
Olanzapine administered with lithium or valproate resulted in increased levels ( 10 %) of tremor, dry mouth, increased appetite, and weight gain.
Olanzapin dan z litijem ali valproatom je povzročil zvišane ravni (≥ 10 %) tresenja, suhih ust, povečanega apetita in povečanja telesne mase.
Olanzapine administered with lithium or valproate resulted in increased levels ( 10%) of tremor, dry mouth, increased appetite, and weight gain.
Olanzapin dan z litijem ali valproatom je povzročil zvišane ravni (≥ 10 %) tresenja, suhih ust, povečanega apetita in povečanja telesne mase.
Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
Peroralni olanzapin je prav tako pokazal rezultate učinkovitosti, primerljive s haloperidolom, glede na delež bolnikov v simptomatski remisiji manije in depresije po 6 in 12 tednih.
Olanzapine Apotex 10 mg are white, round biconvex film-coated tablets engraved ‘APO’ on one side and ‘OLA’ over ‘10’ on the other side.
Olanzapin Apotex 10 mg so bele, okrogle, bikonveksne filmsko obložene tablete z vtisnjenim napisom "APO" na eni strani in "OLA" nad "10" na drugi strani
Olanzapine Apotex 10 mg film-coated tablet
Olanzapin Apotex 10 mg filmsko obložena tableta
Olanzapine Apotex 10 mg film-coated tablets
Olanzapin Apotex 10 mg filmsko obložene tablete
Olanzapine Apotex 10 mg film-coated tablets olanzapine
Olanzapin Apotex 10 mg filmsko obložene tablete olanzapin
Olanzapine Apotex 10 mg orodispersible tablet
Olanzapin Apotex 10 mg orodisperzibilna tableta
Olanzapine Apotex 10 mg orodispersible tablets
Olanzapin Apotex 10 mg orodisperzibilne tablete
Olanzapine Apotex 10 mg orodispersible tablets are yellow round flat faced radial edge tablets engraved ‘APO’ on one side and ‘OL’ over ‘10’ on the other side.
Olanzapin Apotex 10 mg orodisperzibilne tablete so rumene, okrogle, ravne tablete s krožnim krožnim robom in vtisnjenim napisom "APO" na eni strani in "OL" nad "10" na drugi strani
Olanzapine Apotex 10 mg orodispersible tablets olanzapine
Olanzapin Apotex 10 mg orodisperzibilne tablete olanzapin
Olanzapine Apotex 15 mg orodispersible tablet
Olanzapin Apotex 15 mg orodisperzibilna tableta
Olanzapine Apotex 15 mg orodispersible tablets
Olanzapin Apotex 15 mg orodisperzibilne tablete
Olanzapine Apotex 15 mg orodispersible tablets are available in blisters packs of 28 tablets.
Olanzapin Apotex 15 mg orodisperzibilne tablete so na voljo v škatli s pretisnim omotom po 28 tablet.
Olanzapine Apotex 15 mg orodispersible tablets are yellow round flat faced radial edge tablets engraved ‘APO’ on one side and ‘OL’ over ‘15’ on the other side
Olanzapin Apotex 15 mg orodisperzibilne tablete so rumene, okrogle, ravne tablete s krožnim krožnim robom in vtisnjenim napisom "APO" na eni strani in "OL" nad "15" na drugi strani
Olanzapine Apotex 15 mg orodispersible tablets olanzapine
Olanzapin Apotex 15 mg orodisperzibilne tablete olanzapin
Olanzapine Apotex 2.5 mg are white, round, biconvex film-coated tablets engraved ‘APO’ on one side and ‘OLA’ over ‘2.5’ on the other side.
Olanzapin Apotex 2,5 mg so bele, okrogle, bikonveksne filmsko obložene tablete z vtisnjenim napisom "APO" na eni strani in "OLA" nad "2.5" na drugi strani
Olanzapine Apotex 2.5 mg film-coated tablet
Olanzapin Apotex 2,5 mg filmsko obložena tableta
Olanzapine Apotex 2.5 mg film-coated tablets
Olanzapin Apotex 2,5 mg filmsko obložene tablete
Olanzapine Apotex 2.5 mg film-coated tablets are available in blisters packs of 28 tablets.
Olanzapin Apotex 2,5 mg filmsko obložene tablete so na voljo v škatli s pretisnim omotom po 28 tablet.
Olanzapine Apotex 2.5 mg film-coated tablets olanzapine
Olanzapin Apotex 2,5 mg filmsko obložene tablete olanzapin
Olanzapine Apotex 2.5 mg film-coated tablets Olanzapine Apotex 5 mg film-coated tablets Olanzapine Apotex 7.5 mg film-coated tablets Olanzapine Apotex 10 mg film-coated tablets
Olanzapin Apotex 2,5 mg filmsko obložene tablete Olanzapin Apotex 5 mg filmsko obložene tablete Olanzapin Apotex 7,5 mg filmsko obložene tablete Olanzapin Apotex 10 mg filmsko obložene tablete
Olanzapine Apotex 20 mg orodispersible tablet
Olanzapin Apotex 20 mg orodisperzibilna tableta
Olanzapine Apotex 20 mg orodispersible tablets
Olanzapin Apotex 20 mg orodisperzibilne tablete
Olanzapine Apotex 20 mg orodispersible tablets are available in blister packs of 28 and 56 tablets.
Olanzapin Apotex 20 mg orodisperzibilne tablete so na voljo v škatli s pretisnim omotom po 28 in 56 tablet.
Olanzapine Apotex 20 mg orodispersible tablets are yellow round flat faced radial edge tablets engraved ‘APO’ on one side and ‘OL’ over ‘20’ on the other side.
Olanzapin Apotex 20 mg orodisperzibilne tablete so rumene, okrogle, ravne tablete s krožnim krožnim robom in vtisnjenim napisom "APO" na eni strani in "OL" nad "20" na drugi strani
Olanzapine Apotex 20 mg orodispersible tablets olanzapine
Olanzapin Apotex 20 mg orodisperzibilne tablete olanzapin
Olanzapine Apotex 5 mg and 10 mg film- coated tablets are available in blister packs of 28, 56 and 98 tablets..
Olanzapin Apotex 5 mg in 10 mg filmsko obložene tablete so na voljo v škatli s pretisnim omotom po 28, 56 in 98 tablet.
Olanzapine Apotex 5 mg and 10 mg orodispersible tablets are available in blisters packs of 28 , 56 and 98 tablets.
Olanzapin Apotex 5 mg in 10 mg orodisperzibilne tablete so na voljo v škatli s pretisnim omotom po 28, 56 in 98 tablet.
Olanzapine Apotex 5 mg are white, round biconvex film-coated tablets engraved ‘APO’ on one side and ‘OLA’ over ‘5’ on the other side.
Olanzapin Apotex 5 mg so bele, okrogle, bikonveksne filmsko obložene tablete z vtisnjenim napisom "APO" na eni strani in "OLA" nad "5" na drugi strani
Olanzapine Apotex 5 mg film-coated tablet
Olanzapin Apotex 5 mg filmsko obloženea tableta
Olanzapine Apotex 5 mg film-coated tablets
Olanzapin Apotex 5 mg filmsko obložene tablete
Olanzapine Apotex 5 mg film-coated tablets olanzapine
Olanzapin Apotex 5 mg filmsko obložene tablete olanzapin
Olanzapine Apotex 5 mg orodispersible tablet
Olanzapin Apotex 5 mg orodisperzibilna tableta
Olanzapine Apotex 5 mg orodispersible tablets
Olanzapin Apotex 5 mg orodisperzibilne tablete
Olanzapine Apotex 5 mg orodispersible tablets are yellow round flat faced radial edge tablets engraved ‘APO’ on one side and ‘OL’ over ‘5’ on the other side.
Olanzapin Apotex 5 mg orodisperzibilne tablete so rumene, okrogle, ravne tablete s krožnim krožnim robom in vtisnjenim napisom "APO" na eni strani in "OL" nad "5" na drugi strani
Olanzapine Apotex 5 mg orodispersible tablets olanzapine
Olanzapin Apotex 5 mg orodisperzibilne tablete olanzapin
Olanzapine Apotex 5 mg orodispersible tablets Olanzapine Apotex 10 mg orodispersible tablets Olanzapine Apotex 15 mg orodispersible tablets Olanzapine Apotex 20 mg orodispersible tablets
Olanzapin Apotex 5 mg orodisperzibilne tablete Olanzapin Apotex 10 mg orodisperzibilne tablete Olanzapin Apotex 15 mg orodisperzibilne tablete Olanzapin Apotex 20 mg orodisperzibilne tablete
Olanzapine Apotex 7.5 mg are white, round biconvex film-coated tablets engraved ‘APO’ on one side and ‘OLA’ over ‘7.5’ on the other side.
Olanzapin Apotex 7,5 mg so bele, okrogle, bikonveksne filmsko obložene tablete z vtisnjenim napisom "APO" na eni strani in "OLA" nad "7.5" na drugi strani
Olanzapine Apotex 7.5 mg film-coated tablet
Olanzapin Apotex 7,5 mg filmsko obložena tableta
Olanzapine Apotex 7.5 mg film-coated tablets
Olanzapin Apotex 7,5 mg filmsko obložene tablete
Olanzapine Apotex 7.5 mg film-coated tablets are available in blisters packs of 28 and 56 tablets.
Olanzapin Apotex 7,5 mg filmsko obložene tablete so na voljo v škatli s pretisnim omotom po 28 in 56 tablet.
Olanzapine Apotex 7.5 mg film-coated tablets olanzapine
Olanzapin Apotex 7,5 mg filmsko obložene tablete olanzapin
Olanzapine Apotex is a ‘generic medicine’.
Zdravilo Olanzapine Apotex je „generično zdravilo“.
Olanzapine Apotex is not for patients who are under 18 years.
Zdravilo Olanzapin Apotex ni namenjeno bolnikom, mlajšim od 18 let.
Olanzapine Apotex with alcohol
Zdravilo Olanzapin Apotex skupaj z alkoholom
Olanzapine belongs to a group of medicines called antipsychotics and is used to treat the following conditions:
Olanzapin spada v skupino zdravil, imenovanih antipsihotiki in se
Olanzapine Cipla 10 mg coated tablets
Olanzapin Cipla 10 mg obložene tablete
Olanzapine Cipla 10 mg coated tablets are white, round, biconvex, coated tablets with ‘OLZ 10’ debossed on one side and ‘NEO’ on the other.
OLANZAPIN CIPLA 10 mg obložene tablete so bele, okrogle, bikonveksne, obložene tablete z vtisnjeno oznako 'OLZ 10' na eni strani in 'NEO' na drugi.
Olanzapine Cipla 15 mg coated tablets
Olanzapin Cipla 15 mg obložene tablete
Olanzapine Cipla 15 mg coated tablets are blue, elliptical, convex, coated tablets with ‘NEO’ debossed on one side and plain on the other side.
OLANZAPIN CIPLA 15 mg obložene tablete so modre, okrogle, eliptične, obložene tablete z vtisnjeno oznako 'NEO' na eni in brez oznake na drugi strani.
Olanzapine Cipla 2.5 mg coated tablets
Olanzapin Cipla 2,5 mg obložene tablete
Olanzapine Cipla 2.5 mg coated tablets are white, round, biconvex, coated tablets with ‘2.5’ debossed on one side and ‘OLZ’ on the other.
OLANZAPIN CIPLA 2,5 mg obložene tablete so bele, okrogle, bikonveksne, obložene tablete z vtisnjeno oznako '2,5' na eni strani in 'OLZ' na drugi.
Olanzapine Cipla 5 mg coated tablets
Olanzapin Cipla 5 mg obložene tablete
Olanzapine Cipla 5 mg coated tablets are white, round, biconvex, coated tablets with ‘OLZ 5’ debossed on one side and ‘NEO’ on the other.
OLANZAPIN CIPLA 5 mg obložene tablete so bele, okrogle, bikonveksne, obložene tablete z vtisnjeno oznako 'OLZ' na eni strani in 'NEO' na drugi.
Olanzapine Cipla 7.5 mg coated tablets
Olanzapin Cipla 7,5 mg obložene tablete
Olanzapine Cipla 7.5 mg coated tablets are white, round, biconvex, coated tablets with ‘OLZ 7.5’ debossed on one side and ‘NEO’ on the other.
OLANZAPIN CIPLA 7,5 mg obložene tablete so bele, okrogle, bikonveksne, obložene tablete z vtisnjeno oznako 'OLZ 7,5' na eni strani in 'NEO' na drugi.
OLANZAPINE CIPLA contains lactose.
Zdravilo OLANZAPIN CIPLA vsebuje laktozo:
Olanzapine Cipla is a ‘generic medicine’.
Olanzapine Cipla je „generično zdravilo“.
OLANZAPINE CIPLA is not for patients who are under 18 years.
Zdravilo OLANZAPIN CIPLA ni namenjeno bolnikom, mlajšim od 18 let.
OLANZAPINE CIPLA with alcohol
Jemanje zdravila OLANZAPIN CIPLA skupaj z alkoholom
Olanzapine demonstrated a greater in vitro affinity for serotonin 5-HT2 than dopamine D2 receptors and greater 5- HT2 than D2 activity in vivo, models.
V pogojih in vitro je olanzapin pokazal večjo afiniteto za serotoninske 5-HT2 kot za dopaminske D2 receptorje in večjo 5-HT2 kot D2 aktivnost v modelih in vivo.
Olanzapine demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5HT2 than D2 activity in vivo models.
V pogojih in vitro je olanzapin pokazal večjo afiniteto za serotoninske 5-HT2 kot za dopaminske D2 receptorje in večjo 5-HT2 kot D2 aktivnost v modelih in vivo.
Olanzapine demonstrated a greater in-vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5 HT2 than D2 activity in vivo models.
V pogojih in vitro je olanzapin pokazal večjo afiniteto za serotoninske 5-HT2 kot za dopaminske D2 receptorje in večjo 5-HT2 kot D2 aktivnost v modelih in vivo.
Olanzapine does not inhibit the main CYP450 isoenzymes in vitro (e.g.
Olanzapin ne zavira glavnih izoencimov CYP450 v pogojih in vitro (npr.
Olanzapine does not inhibit the main CYP450 isoenzymes in vitro (e.g.
Olanzapin v pogojih in vitro ne zavira delovanja glavnih izoencimov citokroma P450 (npr.
Olanzapine Glenmark
Olanzapie Glenmark
Olanzapine Glenmark
Olanzapin Glenmark
Olanzapine Glenmark 10 mg: yellow coloured circular flat bevelled edge tablets with ‘OL’ debossed on one side and ‘4’ debossed on other side.
Olanzapin Glenmark 10 mg: rumena, okrogla, ploščata tableta z zaobljenim robom, z oznako 'OL' na eni strani in oznako '4' na drugi strani.
Olanzapine Glenmark 15 mg: yellow coloured circular flat bevelled edge tablets with ‘OL’ debossed on one side and ‘5’ debossed on other side.
Olanzapin Glenmark 15 mg: rumena, okrogla, ploščata tableta z zaobljenim robom, z oznako 'OL' na eni strani in oznako '5' na drugi strani.
Olanzapine Glenmark 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg are available in aluminium foil blisters of 28, 56, and 70 tablets
Olanzapin Glenmark 2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg tablete so na voljo v aluminijastih pretisnih omotih po 28, 56 in 70 tablet.
Olanzapine Glenmark 2.5mg is supplied as: yellow coloured circular flat bevelled edge tablets with ‘1’ debossed on one side.
Olanzapin Glenmark 2,5 mg je na voljo kot: rumena, okrogla, ploščata tableta z zaobljenim robom in oznako '1' na eni strani.
Olanzapine Glenmark 20 mg tablets are available in aluminium foil blisters of 28, 35, 56 and 70 tablets
Olanzapin Glenmark 20 mg tablete so na voljo v aluminijastih pretisnih omotih po 28, 35, 56 in 70 tablet.
Olanzapine Glenmark 20 mg: yellow coloured circular flat bevelled edge tablets with ‘OL’ debossed on one side and ‘6’ debossed on other side.
Olanzapin Glenmark 20 mg: rumena, okrogla, ploščata tableta z zaobljenim robom, z oznako 'OL' na eni strani in oznako '6' na drugi strani.
Olanzapine Glenmark 5 mg: yellow coloured circular flat bevelled edge tablets with ‘2’ debossed on one side.
Olanzapin Glenmark 5 mg: rumena, okrogla, ploščata tableta z zaobljenim robom in oznako '2' na eni strani.
Olanzapine Glenmark 7.5 mg: yellow coloured circular flat bevelled edge tablets with ‘3’ debossed on one side.
Olanzapin Glenmark 7,5 mg: rumena, okrogla, ploščata tableta z zaobljenim robom in oznako '3' na eni strani.
Olanzapine Glenmark contains a source of phenylalanine.
Zdravilo Olanzapin Glenmark vsebuje vir fenilalanina.
Olanzapine Glenmark contains aspartame
Zdravilo Olanzapin Glenmark vsebuje aspartam
Olanzapine Glenmark Europe
Olanzapin Glenmark Europe
Olanzapine Glenmark Europe 10 mg orodispersible tablets
Olanzapin Glenmark Europe 10 mg orodisperzibilne tablete
Olanzapine Glenmark Europe 10 mg: yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL’ debossed on one side and ‘4’ debossed on other side.
Olanzapin Glenmark Europe 10 mg: rumena, okrogla, ploščata tableta z zaobljenim robom, z oznako 'OL' na eni strani in oznako '4' na drugi strani.
Olanzapine Glenmark Europe 15 mg orodispersible tablets
Olanzapin Glenmark Europe 15 mg orodisperzibilne tablete
Olanzapine Glenmark Europe 15 mg: yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL’ debossed on one side and ‘5’ debossed on other side.
Olanzapin Glenmark Europe 15 mg: rumena, okrogla, ploščata tableta z zaobljenim robom, z oznako 'OL' na eni strani in oznako '5' na drugi strani.
Olanzapine Glenmark Europe 20 mg orodispersible tablets
Olanzapin Glenmark Europe 20 mg orodisperzibilne tablete
Olanzapine Glenmark Europe 20 mg: yellow coloured circular flat bevelled edge orodispersible tablets with ‘OL’ debossed on one side and ‘6’ debossed on other side.
Olanzapin Glenmark Europe 20 mg: rumena, okrogla, ploščata tableta z zaobljenim robom, z oznako 'OL' na eni strani in oznako '6' na drugi strani.
Olanzapine Glenmark Europe 5 mg orodispersible tablets
Olanzapin Glenmark Europe 5 mg orodisperzibilne tablete
Olanzapine Glenmark Europe 5mg is supplied as: yellow coloured circular flat bevelled edge orodispersible tablets with ‘2’ debossed on one side.
Olanzapin Glenmark Europe 5 mg je na voljo kot: rumena, okrogla, ploščata tableta z zaobljenim robom in oznako '2' na eni strani.
Olanzapine Glenmark Europe contains a source of phenylalanine.
Zdravilo Olanzapin Glenmark Europe vsebuje vir fenilalanina.
Olanzapine Glenmark Europe contains aspartame
Zdravilo Olanzapin Glenmark Europe vsebuje aspartam
Olanzapine Glenmark Europe is a ‘generic medicine’.
Olanzapine Glenmark Europe je „generično zdravilo“.
Olanzapine Glenmark Europe is not for patients who are under 18 years.
Zdravilo Olanzapin Glenmark Europe ni namenjeno bolnikom, mlajšim od 18 let.
Olanzapine Glenmark Europe with alcohol
Jemanje zdravila Olanzapin Glenmark Europe skupaj alkoholom
Olanzapine Glenmark is a ‘generic medicine’.
Olanzapine Glenmark je „generično zdravilo“.
Olanzapine Glenmark is not for patients who are under 18 years.
Zdravilo Olanzapin Glenmark ni namenjeno bolnikom, mlajšim od 18 let.
Olanzapine Glenmark tablets are for oral use.
Olanzapin Glenmark obložene tablete so za peroralno uporabo.
Olanzapine Glenmark with alcohol
Jemanje zdravila Olanzapin Glenmark skupaj alkoholom
Olanzapine is an antipsychotic, antimanic and mood stabilising agent that demonstrates a broad pharmacologic profile across a number of receptor systems.
Olanzapin je antipsihotik, antimanik in stabilizator razpoloženja,, ki kaže širok farmakološki profil prek številnih receptorskih sistemov.
Olanzapine is not approved for the treatment of dementia-related psychosis and/or behavioural disturbances and is not recommended for use in this particular group of patients because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni odobren za zdravljenje bolnikov s psihozo, povezano z demenco in/ali vedenjskimi motnjami ter ni priporočljiv za uporabo pri teh skupinah bolnikov zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni priporočljiv za uporabo bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami, zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke
Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami, zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco, in/ali vedenjskimi motnjami zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco, in/ali vedenjskimi motnjami zaradi povečane umrljivosti in tveganja za možganskožilne dogodke.
Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni priporočljiv za uporabo pri pri bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
Olanzapine is not recommended for use in this patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami, zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
Olanzapine is not recommended for use patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke
Olanzapine is not recommended for use patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.
Olanzapin ni priporočljiv za uporabo pri bolnikih s psihozo, povezano z demenco in/ali vedenjskimi motnjami zaradi povečane umrljivosti in tveganja za cerebrovaskularne dogodke.
Olanzapine may antagonise the effects of direct and indirect dopamine agonists (see section 6.2).
Olanzapin lahko nasprotuje učinkom direktnih in indirektnih dopaminskih agonistov (glejte poglavje 6.2).
Olanzapine may antagonise the effects of direct and indirect dopamine agonists.
Olanzapin lahko zmanjša učinek neposrednih in posrednih dopaminskih agonistov.
Olanzapine Mylan
EU/1/08/475/023